WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC: ACTC) announced today that it has entered into a definitive agreement with Transition Holdings Ltd, an Irish institutional investor, under which it will sell $500,000 of one-year 7% convertible debentures over the next 90 days. The Company will use the proceeds for working capital, general corporate purposes and to continue the development of its most advanced clinical programs. The Company continues to seek partners to jointly develop its pre-clinical and certain clinical programs in heart failure, retinal disease and the production of red blood cells.
